Browsing by Author "Ramírez, Juan Carlos"
Now showing 1 - 1 of 1
Results Per Page
Sort Options
Publication Hematologic β-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity.(American Association for Cancer Research (AACR), 2012-09-15) Leandro-García, Luis J; Leskelä, Susanna; Inglada-Pérez, Lucía; Landa, Iñigo; de Cubas, Aguirre A; Maliszewska, Agnieszka; Comino-Méndez, Iñaki; Letón, Rocío; Gómez-Graña, Álvaro; Torres, Raúl; Ramírez, Juan Carlos; Álvarez, Sara; Rivera, José; Martínez, Constantino; Lozano, María Luisa; Cascón, Alberto; Robledo Batanero, Mercedes; Rodriguez Antona, Cristina; Ministerio de Ciencia e Innovación (España)Cellular microtubules composed of α-β-tubulin heterodimers that are essential for cell shape, division, and intracellular transport are valid targets for anticancer therapy. However, not all the conserved but differentially expressed members of the β-tubulin gene superfamily have been investigated for their role in these settings. In this study, we examined roles for the hematologic isoform β-tubulin VI and functional genetic variants in the gene. β-tubulin VI was highly expressed in blood cells with a substantial interindividual variability (seven-fold variation in mRNA). We characterized DNA missense variations leading to Q43P, T274M, and R307H, and a rare nonsense variant, Y55X. Because variations in the hematologic target of microtubule-binding drugs might alter their myelosuppressive action, we tested their effect in cell lines stably expressing the different β-tubulin VI full-length variants, finding that the T274M change significantly decreased sensitivity to paclitaxel-induced tubulin polymerization. Furthermore, patients treated with paclitaxel and carrying β-tubulin VI T274M exhibited a significantly lower thrombocytopenia than wild-type homozygous patients (P = 0.031). Together, our findings define β-tubulin VI as a hematologic isotype with significant genetic variation in humans that may affect the myelosuppresive action of microtubule-binding drugs. A polymorphism found in a tubulin isoform expressed only in hemapoietic cells may contribute to the patient variation in myelosuppression that occurs after treatment with microtubule-binding drugs.